Canine Parvovirus Monoclonal Antibody

CPMA is approved under a conditional license from the USDA. Safety and efficacy testing are complete for this product and product potency testing remains outstanding for full license.

Like a dog’s own antibodies, CPMA is a synthetic antibody that binds to canine parvovirus. When CPMA binds, it neutralizes parvovirus before the virus can enter the cell.^1,2 CPMA essentially delivers an immediate high level of defense against parvovirus.

1. Organtini LJ, Lee H, Iketani S, et al. Near-atomic resolution structure of a highly neutralizing Fab bound to canine parvovirus. J Virol. 2016;90(21):9733-42. doi:10.1128/JVI.01112-16.
2. Nelson CDS, Palermo LM, Hafenstein SL, Parrish CR. Different mechanisms of antibody-mediated neutralization of parvoviruses revealed using the Fab fragments of monoclonal antibodies. Virology. 2007;361(2):283-93. doi:10.1016/j.virol.2006.11.032.

CPMA demonstrated 100% efficacy in prevention of mortality associated with canine parvovirus infection when administered as a sole therapy at first test positive of parvovirus antigen in the feces in the treatment efficacy study.¹ Additionally, CPMA-treated dogs had significantly faster times to resolution of vomiting, lethargy and lack of appetite.³

1. Canine Parvovirus Monoclonal Antibody Product Insert.
3. Elanco Animal Health. Data on file.

Field safety data analysis of 147 client-owned dogs of various breeds, ranging from 6 weeks of age to 15 years and weighing between 0.6-59.2 kg (1.3-130 lbs.), and located in nine separate sites concluded the product is well-tolerated when administered to healthy dogs by the intravenous route. No anaphylactic reactions or clinical presentations consistent with anaphylaxis were reported.¹

1. Canine Parvovirus Monoclonal Antibody Product Insert.

CPMA is labeled for use in dogs 8 weeks of age and older. The dogs in the treatment efficacy study were 8 weeks of age.¹ In the field safety study, the youngest dogs receiving IV CPMA were 6 weeks of age.¹ Use of the product under 8 weeks of age is considered off label use, cannot be recommended by Elanco and would be at the veterinarian's discretion.

1. Canine Parvovirus Monoclonal Antibody Product Insert.

The treatment of canine parvovirus often includes multiple medications. There are no known drug interactions with CPMA and veterinary medications.

Currently it is not known how long CPMA will interfere with vaccination. Along with active immunity initiated by the naturally occurring parvovirus infection, the use of this monoclonal antibody as therapeutic treatment may interfere with subsequent parvovirus vaccination. For advice on parvovirus vaccination scheduling after use, consult your veterinarian.¹

1. Canine Parvovirus Monoclonal Antibody Product Insert.

In a clinical field safety trial, most side effects were mild and most dogs recovered within one day. Three dogs took 2-4 days to recover. One dog had continuing site inflammation until study exit (14 days after injection). For more complete information regarding safety and all possible adverse events, see productdata.aphis.usda.gov. The most common adverse reactions reported were injection site reactions (4%).¹

1. Canine Parvovirus Monoclonal Antibody Product Insert.